Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | IDH1 | O75874 | 12/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | IDH2 | P48735 | 3/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22795799 | 0.93 | ADRB1 (0.48) | ADRB1IDH1P2RX7IDH2GRM5 | |
| SCHEMBL18763962 | 0.86 | ADRB1 (0.45) | ADRB1IDH1P2RX7GRM5 | |
| SCHEMBL20738182 | 0.85 | ADRB1 (0.49) | ADRB1IDH1P2RX7IDH2GRM5 | |
| SCHEMBL12264474 | 0.83 | ADRB1 (0.48) | ADRB1IDH1P2RX7IDH2GRM5 | |
| Hydrochloric Acid SCHEMBL2401971 | 0.82 | IRAK4 (0.47) | ADRB1IDH1P2RX7IDH2GRM5 | |
| SCHEMBL24302842 | 0.79 | ADRB1 (0.47) | ADRB1IDH1P2RX7IDH2GRM5 | |
| SCHEMBL15354799 | 0.77 | ADRB1 (0.51) | ADRB1IDH1P2RX7IDH2GRM5 | |
| SCHEMBL26304397 | 0.77 | HRH1 (0.35) | — | |
| SCHEMBL9991096 | 0.76 | ADRB1 (0.50) | ADRB1IDH1P2RX7IDH2GRM5 | |
| SCHEMBL9991717 | 0.76 | ADRB1 (0.66) | ADRB1IDH1P2RX7IDH2GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210236442-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210236442-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | IAPP, SLC5A2, SLC2A2 | ADRB1 1733/4885IDH1 4673/4885P2RX7 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.